Evidence map›Paper›PMID 27405513›Full record

ArticleInternational journal of clinical oncology2016

The value of circulating CYFRA21-1 expression in patients with nasopharyngeal carcinoma: a study of 529 subjects.

Xin-Mao Song, Zhu-Jian Wang, Wen-Jun Cao, Ji-Li, Fu Chen, Sheng-Zi Wang

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Xin-Mao SongDepartment of Radiation Oncology, Eye, Ear, Nose and Throat, FuDan University, Fenyang Road 83, Shanghai, 200031, China.
Zhu-Jian WangDepartment of Clinical Laboratory, Eye, Ear, Nose and Throat, FuDan University, Fenyang Road 83, Shanghai, 200031, China.
Wen-Jun CaoDepartment of Clinical Laboratory, Eye, Ear, Nose and Throat, FuDan University, Fenyang Road 83, Shanghai, 200031, China.
Ji-LiDepartment of Radiation Oncology, Eye, Ear, Nose and Throat, FuDan University, Fenyang Road 83, Shanghai, 200031, China.
Fu ChenDepartment of Radiation Oncology, Eye, Ear, Nose and Throat, FuDan University, Fenyang Road 83, Shanghai, 200031, China.
Sheng-Zi WangDepartment of Radiation Oncology, Eye, Ear, Nose and Throat, FuDan University, Fenyang Road 83, Shanghai, 200031, China. shengziwang@fudan.edu.cn.
Fudan University · CNMinistry of Health · OM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEarly diagnosis of nasopharyngeal carcinoma (NPC) needs more reliable biomarkers. The aim of this study was to investigate serum cytokeratin 19 fragment 21.1 (CYFRA21-1) as an NPC biomarker based on data from a large sample.

methodsFrom October 2010 to February 2014, 529 subjects were enrolled and divided into three groups-NPC group (n = 274), healthy control group (n = 175) and nasal inflammatory disease group (n = 80). Serum CYFRA21-1 levels were measured prior to radiotherapy/chemoradiotherapy, and their associations with T, N, and clinical classification were determined. Receiver operating characteristic curve analysis was performed to discriminate the NPC group from the healthy control and nasal inflammatory disease groups. Three Epstein-Barr virus (EBV) antibodies and their correlations with serum CYFRA21-1 levels were analyzed.

resultsPretreatment serum CYFRA21-1 levels were significantly elevated in the NPC group compared with the other groups (p < 0.01), Furthermore, serum CYFRA21-1 levels decreased significantly after radiotherapy (p < 0.01). Serum CYFRA21-1 levels were closely related to T, N, and clinical classifications. The area under the curve, sensitivity and specificity of the serum CYFRA21-1 levels in the NPC patients were 0.89, 0.87 and 0.83, respectively. Strong correlations were observed between serum CYFRA21-1 levels and EBV antibodies.

conclusionSerum CYFRA21-1 may be a reliable and effective biomarker for NPC.

Indexed as

Nasopharyngeal NeoplasmsAdultAntibodies, ViralAntigens, NeoplasmBiomarkers, TumorCarcinomaChemoradiotherapyFemaleHerpesvirus 4, HumanHumansKeratin-19MaleMiddle AgedNasopharyngeal CarcinomaNeoplasm StagingPatient Outcome AssessmentAntibodies, Viralantigen CYFRA21.1Antigens, NeoplasmBiomarkers, TumorKeratin-19Cytokeratin 19 fragment 21.1Epstein–Barr virus antibodiesNasopharyngeal carcinomaTumor biomarker

Identifiers

PMID27405513
OpenAlexW2464025774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.